

Andrew G Renehan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6757355/andrew-g-renehan-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

13,794
citations

49
h-index

116
g-index

185
ext. papers

16,076
ext. citations

9
avg, IF

6.53
L-index

#	Paper	IF	Citations
172	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial.. <i>BMC Medicine</i> , 2022 , 20, 59	11.4	1
171	Clinico-pathological predictors of clinical complete response in rectal cancer.. <i>Cancer Treatment and Research Communications</i> , 2022 , 31, 100540	2	2
170	Associations of specific-age and decade recall body mass index trajectories with obesity-related cancer. <i>BMC Cancer</i> , 2021 , 21, 502	4.8	0
169	Cancer survivorship, excess body fatness and weight-loss intervention-where are we in 2020?. <i>British Journal of Cancer</i> , 2021 , 124, 1057-1065	8.7	5
168	Cancer prevention through weight control-where are we in 2020?. <i>British Journal of Cancer</i> , 2021 , 124, 1049-1056	8.7	3
167	Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. <i>Lancet Oncology, The</i> , 2021 , 22, 43-50	21.7	31
166	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 805-816	19.4	10
165	Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy. <i>Surgical Oncology</i> , 2021 , 38, 101572	2.5	0
164	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 1087-1100	10.3	13
163	Weight Changes in Type 2 Diabetes and Cancer Risk: A Latent Class Trajectory Model Study.. <i>Obesity Facts</i> , 2021 , 1-10	5.1	0
162	Cancer and cardiovascular disease. <i>Lancet, The</i> , 2020 , 395, 1903-1904	40	1
161	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom). <i>British Journal of Cancer</i> , 2020 , 122, 1552-1561	8.7	7
160	Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence. <i>Clinical Oncology</i> , 2020 , 32, 591-608	2.8	17
159	Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014). <i>British Journal of Cancer</i> , 2020 , 122, 749-758	8.7	3
158	Watch and wait or surgery for clinical complete response in rectal cancer: a need to study both sides. <i>Colorectal Disease</i> , 2020 , 22, 839-840	2.1	2
157	Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLIFF Study. <i>BMJ Open</i> , 2020 , 10, e027630	3	2
156	Three-dimensional (3D) magnetic resonance volume assessment and loco-regional failure in anal cancer: early evaluation case-control study. <i>BMC Cancer</i> , 2020 , 20, 1165	4.8	

155	Interaction between co-morbidities and cancer survival. <i>European Journal of Epidemiology</i> , 2019 , 34, 1103-1105	21.1	1054
154	Top ten research priorities for detecting cancer early. <i>Lancet Public Health, The</i> , 2019 , 4, e551	22.4	16
153	Early stage anal margin cancer: towards evidence-based management. <i>Colorectal Disease</i> , 2019 , 21, 387-391	3.9	5
152	Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial. <i>European Journal of Cancer</i> , 2019 , 117, 48-59	7.5	1
151	Awareness of the link between obesity and cancer in UK school curricula. <i>Lancet, The</i> , 2019 , 393, 1591-1592	11.9	4
150	Cancer surveillance, obesity, and potential bias. <i>Lancet Public Health, The</i> , 2019 , 4, e218	22.4	
149	COSMOS-E: Guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. <i>PLoS Medicine</i> , 2019 , 16, e1002742	11.6	139
148	Referral pathways and outcome of patients with colorectal peritoneal metastasis (CRPM). <i>European Journal of Surgical Oncology</i> , 2019 , 45, 2310-2315	3.6	3
147	Watch-and-wait strategy in rectal cancer - AuthorsPreply. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 97	18.8	1
146	Linkage of the UK Clinical Practice Research Datalink with the national cancer registry. <i>European Journal of Epidemiology</i> , 2019 , 34, 101-102	12.1	3
145	The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. <i>International Journal of Cancer</i> , 2019 , 144, 641-650	7.5	56
144	Development of MR quantified pancreatic fat deposition as a cancer risk biomarker. <i>Pancreatology</i> , 2018 , 18, 429-437	3.8	5
143	Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC). <i>Colorectal Disease</i> , 2018 , 20, 371-382	2.1	11
142	Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: a long-term Danish cohort study. <i>Cancer Medicine</i> , 2018 , 7, 2391-2404	4.8	6
141	Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWW): an international multicentre registry study. <i>Lancet, The</i> , 2018 , 391, 2537-2545	40	364
140	Limitations of the National Cancer Data Base to Evaluate Early-Stage Anal Cancer Treatment Outcomes. <i>JAMA Surgery</i> , 2018 , 153, 691	5.4	4
139	Framework to construct and interpret latent class trajectory modelling. <i>BMJ Open</i> , 2018 , 8, e020683	3	52
138	Body-mass index and metastatic melanoma outcomes. <i>Lancet Oncology, The</i> , 2018 , 19, e225	21.7	3

137 Obesity and dietary approaches to cancer prevention **2018**, 381-402

136	A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 865-873	18.8	35
135	Is "watch-and-wait" after chemoradiotherapy safe in patients with rectal cancer?. <i>BMJ, The</i> , 2018 , 363, k4472	5.9	12
134	Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 825-836	18.8	69
133	Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 2095-2103	27.4	102
132	Change in weight status from childhood to early adulthood and late adulthood risk of colon cancer in men: a population-based cohort study. <i>International Journal of Obesity</i> , 2018 , 42, 1797-1803	5.5	9
131	Excess Weight as a Risk Factor Common to Many Cancer Sites: Words of Caution when Interpreting Meta-analytic Evidence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 663-665	4	10
130	Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer-Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 976	4	
129	Obesity paradox and mortality in adults with and without incident type 2 diabetes: a matched population-level cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2017 , 5, e000369	4.5	14
128	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017 , 30, 459-468	9.8	33
127	Anal cancer: different epidemiological and clinical definitions. <i>International Journal of Epidemiology</i> , 2017 , 46, 2091-2092	7.8	1
126	Childhood body mass index and height in relation to site-specific risks of colorectal cancers in adult life. <i>European Journal of Epidemiology</i> , 2017 , 32, 1097-1106	12.1	24
125	Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Multidisciplinary Management. <i>Colorectal Disease</i> , 2017 , 19 Suppl 1, 37-66	2.1	26
124	Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer. <i>Colorectal Disease</i> , 2017 , 19 Suppl 1, 82-97 ¹	2.1	26
123	Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. <i>Lancet Oncology, The</i> , 2017 , 18, 1348-1359	21.7	28
122	Watch-and-wait approach for rectal cancer: concepts of a subject-specific method. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 627	18.8	2
121	Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer. <i>BMJ Open</i> , 2017 , 7, e018726	3	13
120	The Obesity Paradox in Cancer: a Review. <i>Current Oncology Reports</i> , 2016 , 18, 56	6.3	224

119	Obesity and endometrial cancer: unanswered epidemiological questions. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016 , 123, 175-8	3.7	11
118	Measuring the biological effect of presurgical metformin treatment in endometrial cancer. <i>British Journal of Cancer</i> , 2016 , 114, 281-9	8.7	64
117	Techniques and Outcome of Surgery for Locally Advanced and Local Recurrent Rectal Cancer. <i>Clinical Oncology</i> , 2016 , 28, 103-115	2.8	6
116	Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. <i>Lancet Oncology, The</i> , 2016 , 17, 174-183	21.7	428
115	Obesity as an Avoidable Cause of Cancer (Attributable Risks). <i>Recent Results in Cancer Research</i> , 2016 , 208, 243-256	1.5	16
114	How to Manage the Obese Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4284-4294	2.2	35
113	Watch-and-wait versus surgical resection for patients with rectal cancer - AuthorsPreply. <i>Lancet Oncology, The</i> , 2016 , 17, e134-e135	21.7	5
112	Collider Bias Is Only a Partial Explanation for the Obesity Paradox. <i>Epidemiology</i> , 2016 , 27, 525-30	3.1	69
111	Adiposity and cancer risk: new mechanistic insights from epidemiology. <i>Nature Reviews Cancer</i> , 2015 , 15, 484-98	31.3	343
110	Digital histology quantification of intra-hepatic fat in patients undergoing liver resection. <i>European Journal of Surgical Oncology</i> , 2015 , 41, 1020-7	3.6	7
109	Incremental benefits of screening colonoscopy over sigmoidoscopy in average-risk populations: a model-driven analysis. <i>Cancer Causes and Control</i> , 2015 , 26, 859-70	2.8	6
108	A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S90	4.0	20
107	High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: different implications for vaccine prevention and prognosis. <i>European Journal of Cancer</i> , 2015 , 51, 776-85	7.5	62
106	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. <i>Diabetologia</i> , 2015 , 58, 493-504	10.3	114
105	Global burden of cancer attributable to high body-mass index in 2012: a population-based study. <i>Lancet Oncology, The</i> , 2015 , 16, 36-46	21.7	529
104	Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. <i>European Journal of Cancer</i> , 2015 , 51, 1164-87	7.5	319
103	A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues. <i>Carcinogenesis</i> , 2015 , 36, 1040-50	4.6	12
102	Obesity and cancer: links with survival differ from those with incidence. <i>Annals of Oncology</i> , 2015 , 26, 821	10.3	1

101	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 115-22.e1-2	3.8	36
100	Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 1436-44	3.6	14
99	Diabetes and cancer: 5 years into the recent controversy. <i>European Journal of Cancer</i> , 2014 , 50, 2119-25	7.5	38
98	Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014 , 28, 341-5	5.2	25
97	Slowing down of adult body mass index trend increases in England: a latent class analysis of cross-sectional surveys (1992-2010). <i>International Journal of Obesity</i> , 2014 , 38, 818-24	5.5	57
96	Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. <i>BJU International</i> , 2014 , 114, E70-E73	5.6	23
95	Comment on Bordeleau et al. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> 2014;37:1360-1366. <i>Diabetes Care</i> , 2014 , 37, e221-2	14.6	4
94	Re: Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt375	9.7	7
93	Chronic insulin exposure does not cause insulin resistance but is associated with chemo-resistance in colon cancer cells. <i>Hormone and Metabolic Research</i> , 2014 , 46, 85-93	3.1	10
92	Impact of mechanical bowel preparation on survival after colonic cancer resection (Br J Surg 2014; 101: 1594-1600). <i>British Journal of Surgery</i> , 2014 , 101, 1600-1	5.3	0
91	Excess adiposity and gastrointestinal cancer. <i>British Journal of Surgery</i> , 2014 , 101, 1518-31; discussion 1531	5.3	22
90	Excess adiposity and survival in patients with colorectal cancer: a systematic review. <i>Obesity Reviews</i> , 2014 , 15, 434-51	10.6	49
89	The Obesity paradox and survival after colorectal cancer: true or false?. <i>Cancer Causes and Control</i> , 2014 , 25, 1419-22	2.8	7
88	The interaction between prognostic and pharmacodynamic biomarkers. <i>British Journal of Cancer</i> , 2013 , 109, 1782-5	8.7	
87	Comparison of associations of body mass index, abdominal adiposity, and risk of colorectal cancer in a large prospective cohort study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1383-94	4	41
86	The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. <i>Hpb</i> , 2013 , 15, 463-72	3.8	19
85	Insulin analogues and cancer risk: the emergence of second-generation studies. <i>Diabetologia</i> , 2012 , 55, 7-9	10.3	23
84	FDG PET-CT imaging for pre operative staging in patients with colorectal cancer. <i>The Cochrane Library</i> , 2012 ,	5.2	4

83	Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer. <i>ANZ Journal of Surgery</i> , 2012 , 82, 729-36	1	3
82	Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. <i>European Journal of Cancer</i> , 2012 , 48, 853-64	7.5	71
81	Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. <i>British Journal of Cancer</i> , 2012 , 107, 1518-24	8.7	24
80	Current treatment of anal squamous cell carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2012 , 26, 1315-50	3.1	17
79	Classification of and cytoreductive surgery for low-grade appendiceal mucinous neoplasms. <i>British Journal of Surgery</i> , 2012 , 99, 987-92	5.3	63
78	Body composition and outcome in patients undergoing resection of colorectal liver metastases (Br J Surg 2012; 99: 550-557). <i>British Journal of Surgery</i> , 2012 , 99, 1021-2; author reply 1022	5.3	11
77	Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. <i>Diabetologia</i> , 2012 , 55, 1607-18	10.3	151
76	Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. <i>Diabetologia</i> , 2012 , 55, 1619-32	10.3	97
75	Comment on: Morden et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. <i>Diabetes Care</i> 2011;34:1965-1971. <i>Diabetes Care</i> , 2012 , 35, e15; author reply e16	14.6	3
74	Body mass index at different adult ages, weight change, and colorectal cancer risk in the National Institutes of Health-AARP Cohort. <i>American Journal of Epidemiology</i> , 2012 , 176, 1130-40	3.8	69
73	Cumulative incidence of metachronous colorectal cancer risk for mismatch repair gene mutation carriers is overestimated. <i>Gut</i> , 2012 , 61, 783; author reply 783-4	19.2	3
72	Growth hormone receptor polymorphism and growth hormone therapy response in children: a Bayesian meta-analysis. <i>American Journal of Epidemiology</i> , 2012 , 175, 867-77	3.8	29
71	Re: body mass index and risk of lung cancer among never, former, and current smokers. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1680-1; author reply 1681	9.7	15
70	Height and cancer: consistent links, but mechanisms unclear. <i>Lancet Oncology</i> , 2011 , 12, 716-7	21.7	22
69	Initial management through the anal cancer multidisciplinary team meeting. <i>Colorectal Disease</i> , 2011 , 13 Suppl 1, 21-8	2.1	12
68	Management of local disease relapse. <i>Colorectal Disease</i> , 2011 , 13 Suppl 1, 44-52	2.1	20
67	The development of composite circulating biomarker models for use in anticancer drug clinical development. <i>International Journal of Cancer</i> , 2011 , 128, 1843-51	7.5	7
66	Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 2912-20	5.6	111

65	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. <i>Nature Reviews Endocrinology</i> , 2011 , 7, 11-24	15.2	241
64	The Role of High Frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic Antigen (CEA) Measurements in Colorectal Cancer Surveillance: A (Revisited) Hypothesis Paper. <i>Cancers</i> , 2011 , 3, 2302-15	6.6	8
63	Colorectal cancer incidence trends in the United States and United kingdom: evidence of right- to left-sided biological gradients with implications for screening. <i>Cancer Research</i> , 2010 , 70, 5419-29	10.1	84
62	Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 3119-30	4	190
61	Body fatness and bevacizumab-based therapy in metastatic colorectal cancer. <i>Gut</i> , 2010 , 59, 289-90	19.2	7
60	The long road towards cancer prevention: 4 steps backward and 8 forward. <i>European Journal of Cancer</i> , 2010 , 46, 2660-2	7.5	11
59	Lifestyle changes and reduction of colon cancer incidence in Europe: A scenario study of physical activity promotion and weight reduction. <i>European Journal of Cancer</i> , 2010 , 46, 2605-16	7.5	46
58	Foreword: Implementing cancer prevention in Europe. <i>European Journal of Cancer</i> , 2010 , 46, 2523-4	7.5	7
57	Interpreting the epidemiological evidence linking obesity and cancer: A framework for population-attributable risk estimations in Europe. <i>European Journal of Cancer</i> , 2010 , 46, 2581-92	7.5	75
56	Biological mechanisms linking obesity and cancer risk: new perspectives. <i>Annual Review of Medicine</i> , 2010 , 61, 301-16	17.4	447
55	Linking diabetes and cancer: a consensus on complexity. <i>Lancet, The</i> , 2010 , 375, 2201-2	40	70
54	Obesity and cancer in Asia-Pacific populations. <i>Lancet Oncology, The</i> , 2010 , 11, 704-5	21.7	4
53	Incident cancer burden attributable to excess body mass index in 30 European countries. <i>International Journal of Cancer</i> , 2010 , 126, 692-702	7.5	185
52	Physical Activity Before and After Diagnosis of Colorectal Cancer 2010 , 153-172		
51	Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. <i>Colorectal Disease</i> , 2009 , 11, 547-63	2.1	146
50	Lifestyle factors and colorectal cancer risk (2): a systematic review and meta-analysis of associations with leisure-time physical activity. <i>Colorectal Disease</i> , 2009 , 11, 689-701	2.1	154
49	Bariatric surgery, weight reduction, and cancer prevention. <i>Lancet Oncology, The</i> , 2009 , 10, 640-1	21.7	52
48	Treatments and outcomes of peritoneal surface tumors through a centralized national service (United kingdom). <i>Diseases of the Colon and Rectum</i> , 2009 , 52, 1705-14	3.1	21

47	Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancer. <i>British Journal of Cancer</i> , 2008 , 99, 459-63	8.7	11
46	A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. <i>British Journal of Cancer</i> , 2008 , 99, 591-6	8.7	70
45	Acromegaly, growth hormone and cancer risk. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 639-57	6.5	68
44	Obesity and cancer: pathophysiological and biological mechanisms. <i>Archives of Physiology and Biochemistry</i> , 2008 , 114, 71-83	2.2	315
43	Meta-analysis in medical research: potentials and limitations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 320-9	2.8	46
42	Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. <i>Lancet, The</i> , 2008 , 371, 569-78	4.0	3482
41	Systematic reviews and meta-analyses in coloproctology: interpretation and potential pitfalls. <i>Colorectal Disease</i> , 2008 , 10, 21-32	2.1	9
40	Insulin and Cancer: Report of the Proceedings of the First International Workshop, October 27-28, 2007, Dßseldorf, Germany. <i>Pediatric Endocrinology Reviews</i> , 2008 , 5, 810-6	1.1	2
39	Colorectal cancer prevention: choosing the most effective population strategy using bio-mathematical approaches. <i>Colorectal Disease</i> , 2007 , 9, 393-6	2.1	1
38	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <i>Growth Hormone and IGF Research</i> , 2007 , 17, 210-9	2	5
37	Physical activity before and after diagnosis of colorectal cancer: disease risk, clinical outcomes, response pathways and biomarkers. <i>Sports Medicine</i> , 2007 , 37, 947-60	10.6	33
36	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. <i>Endocrine-Related Cancer</i> , 2006 , 13, 273-8	5.7	111
35	A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei. <i>British Journal of Cancer</i> , 2006 , 95, 1258-64	8.7	29
34	Obesity and cancer risk: the role of the insulin-IGF axis. <i>Trends in Endocrinology and Metabolism</i> , 2006 , 17, 328-36	8.8	362
33	Preventing cancer, cardiovascular disease, and diabetes. <i>Lancet, The</i> , 2005 , 365, 1449-51	4.0	33
32	Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. <i>Clinical Endocrinology</i> , 2005 , 62, 323-30	3.4	19
31	IGF-I, IGF binding protein-3 and breast cancer risk: comparison of 3 meta-analyses. <i>International Journal of Cancer</i> , 2005 , 115, 1006-7; author reply 1008	7.5	34
30	Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. <i>British Journal of Surgery</i> , 2005 , 92, 605-14	5.3	127

29	Insulin-like growth factor-binding protein-3, breast cancer risk, and different serum assays. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1844	4	4
28	Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. <i>British Journal of Cancer</i> , 2005 , 92, 430-3	8.7	50
27	The effect of cigarette smoking use and cessation on serum insulin-like growth factors. <i>British Journal of Cancer</i> , 2004 , 91, 1525-31	8.7	24
26	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. <i>Lancet, The</i> , 2004 , 363, 1346-53	40	1364
25	Guidelines for colonoscopic screening in acromegaly are inconsistent with those for other high risk groups. <i>Gut</i> , 2003 , 52, 1071-2; author reply 1072	19.2	5
24	Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. <i>Hormone and Metabolic Research</i> , 2003 , 35, 712-25	3.1	83
23	Extracapsular dissection for clinically benign parotid lumps: reduced morbidity without oncological compromise. <i>British Journal of Cancer</i> , 2003 , 89, 1610-3	8.7	166
22	Re: Sternomastoid flap after superficial parotidectomy. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2003 , 41, 281	1.4	
21	Determination of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels in serum and plasma: comparisons using the Bland-Altman method. <i>Growth Hormone and IGF Research</i> , 2003 , 13, 341-6	2	26
20	Early cellular events in colorectal carcinogenesis. <i>Colorectal Disease</i> , 2002 , 4, 76-89	2.1	49
19	Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. <i>Clinical Endocrinology</i> , 2002 , 57, 59-64	3.4	27
18	Acromegaly and Colorectal Cancer: Risk Assessment Should Be Based on Population-Based Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 1909-1909	5.6	8
17	High-risk colorectal adenomas and serum insulin-like growth factors. <i>British Journal of Surgery</i> , 2001 , 88, 107-13	5.3	62
16	Screening colonoscopy for acromegaly in perspective. <i>Clinical Endocrinology</i> , 2001 , 55, 731-3	3.4	25
15	Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. <i>Clinical Endocrinology</i> , 2001 , 55, 469-75	3.4	9
14	What is apoptosis, and why is it important?. <i>BMJ: British Medical Journal</i> , 2001 , 322, 1536-8		162
13	Stem cells: the intestinal stem cell as a paradigm. <i>Carcinogenesis</i> , 2000 , 21, 469-76	4.6	261
12	Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated. <i>Gut</i> , 2000 , 46, 440-1	19.2	11

11	Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. <i>British Journal of Cancer</i> , 2000 , 83, 1344-50	8.7	83
10	Surveillance after colorectal cancer resection. <i>Lancet, The</i> , 2000 , 355, 1095-6	4.0	6
9	Circulating Insulin-Like Growth Factor II and Colorectal Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3402-3408	5.6	49
8	Re: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 2051-2	9.7	6
7	Clinico-pathological and treatment-related factors influencing survival in parotid cancer. <i>British Journal of Cancer</i> , 1999 , 80, 1296-300	8.7	115
6	A selective policy in follow-up for bowel cancer. <i>Lancet, The</i> , 1998 , 351, 1891	4.0	
5	An analysis of the treatment of 114 patients with recurrent pleomorphic adenomas of the parotid gland. <i>American Journal of Surgery</i> , 1996 , 172, 710-4	2.7	92
4	Growth hormone, the insulin-like growth factor axis, insulin and cancer risk		1
3	Clinico-pathological and treatment-related factors influencing survival in parotid cancer		24
2	Obesity and Cancer369-384		
1	Hormones, Growth Factors, and Tumor Growth32-40		3